Real-World Comparative Efficacy and Safety of Upadacitinib, Tofacitinib, and Filgotinib in Patients With Ulcerative Colitis - PubMed
6 hours ago
- #real-world study
- #JAK inhibitors
- #ulcerative colitis
- Study compares efficacy and safety of upadacitinib, tofacitinib, and filgotinib in ulcerative colitis (UC) patients.
- Biochemical response (reduction in faecal calprotectin) was highest with upadacitinib (86.4%), followed by tofacitinib (62.5%) and filgotinib (50%).
- Endoscopic reassessment showed improvement or resolution of inflammation, particularly in upadacitinib and tofacitinib groups.
- Safety profile consistent with known JAK inhibitor side effects; hyperlipidemia was the most common adverse event.
- No serious opportunistic infections or thromboembolic events were recorded.
- Upadacitinib demonstrated the strongest overall biochemical response in this treatment-experienced UC cohort.